We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.43 | 4.30% | 10.43 | 9.75 | 44.43 | 10.69 | 10.00 | 10.10 | 900,531 | 05:00:01 |
•
|
“[S]ince the recent SUSAR event, the narrative of this proxy contest has completely turned, in our view, to the point where the board’s case
against the Dissident now appears to be sorely lacking in credibility, while the Dissident’s arguments (particularly that the Company should direct greater attention towards resolving the safety issues of ADVM-022) seemingly carry a great deal of prescience.”
|
•
|
“Considering the recent SUSAR event and the implications thereof, we are inclined to agree with the Dissident’s case for the board change being sought here.”
|
•
|
“In our view, the Dissident has put forth a
compelling slate of director nominees, most of whom have relevant experience and expertise in the medical field, who should be able to help the Company to navigate through its current situation. In particular, we highlight Dissident Nominees Jean Bennett and Jodi Cook, both of whom have a great deal of experience and expertise in the gene therapy field, as
their biographies would attest to…”
|
•
|
“Meanwhile, we note that Dissident Nominee Herbert Hughes has extensive experience in the financial services industry, has held leadership roles
in a diverse range of businesses (gaming, oil services, and investment banking), and currently serves as a director of Byrna Technologies, a publicly-traded defense technology firm. In our view, Mr. Hughes’ background and experience, particularly in financial markets and capital allocation, could help to round out the skill sets of, and provide a complementary perspective to
the Company’s board, particularly one that is heavily weighted towards individuals with backgrounds in various medical fields.”
|
•
|
“[T]he recent SUSAR event has unfortunately laid
bare the Company’s shortcomings in addressing the inflammation issue of its sole product candidate, ADVM-022. In light of the recent developments, we believe that change at the board level is warranted, and that the Dissident
Nominees represent the more compelling slate of director candidates for the Company at this time.”
|
•
|
“Accordingly, we recommend that shareholders vote on the Dissident’s GREEN proxy card FOR all nominees.”
|
If you have any questions regarding your GREEN proxy card or need assistance in voting your shares, please contact
Saratoga Proxy Consulting, LLC
520 8th Avenue
New York, NY 10018
Stockholders may call toll-free: (888) 368-0379
Banks and brokers call: (212)
257-1311
info@saratogaproxy.com
|
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions